- Company
- Entresto faces competition in the heart failure market
- by Moon, sung-ho Aug 19, 2024 05:47am
- As the volume of treatment for patients with heart failure increases due to the aging population, the competition is accelerating in the market for the treatment. This is because there are more treatment options in clinical practices and higher chances of generics entry into the market. According to the medical and pharmaceutical indu
- Company
- Twice-yearly Uplizna enters last stage to reimb in KOR
- by Eo, Yun-Ho Aug 16, 2024 05:56am
- Uplizna, a new drug for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year, has entered the final gateway for insurance reimbursement in Korea. According to industry sources, Mitsubishi Tanabe Pharma Korea entered pricing negotiations with the National Health Insurance Service (NHIS) for Uplizna (inebilizumab
- Company
- OraTicx signs a distribution deal with U.S.-based Stratum
- by Son, Hyung-Min Aug 16, 2024 05:56am
- OraTicx, a company specializing in developing oral probiotics, announced that it has signed an exclusive distribution agreement for the North American region with Stratum Nutrion (hereafter referred to as Stratum), a U.S.-based dietary supplement ingredient supplier. Through this agreement, OraTicx will exclusively distribute its propriet
- Company
- K-Pharma speeds up marketing new drugs for bile duct cancer
- by Son, Hyung-Min Aug 16, 2024 05:55am
- Korean pharmaceutical companies are speeding up the development of new drugs for cholangiocarcinoma (also known as bile duct cancer). Handok's partnering company in the United States, Compass Therapeutics, has recently completed registering patients for the Phase 2/3 trials. Once the efficacy of the novel drug is confirmed, Handok plans to apply
- Company
- LG Chem begins Phase 2 trials for infant hexavalent vaccine
- by Hwang, Byung-woo Aug 14, 2024 05:51am
- LG Chem prepares to commence the Phase 2 clinical trial for its hexavalent vaccine LR20062. The company aims to domestically produce infant combination vaccines in South Korea. Since South Korea has so far relied entirely on imported combination vaccines, the company plans to provide a stable supply network to meet mid- to-long term dema
- Company
- 'Xtandi and Erleada' compete in the prostate cancer market
- by Hwang, Byung-woo Aug 14, 2024 05:51am
- The market for ARTA treatment used to treat prostate cancer has been dominated by Xtandi (enzalutamide). As prescription sales of Erleada (apalutamide) rise, the market is shifting. Astellas Pharma's Xtandi has increased its competitiveness with its indications, Janssen has started to face competition by expanding its portfolio, including Er
- Company
- Nabota accounts for 24% of Daewoong’s ETC sales
- by Chon, Seung-Hyun Aug 13, 2024 05:47am
- Daewoong Pharmaceutical's botulinum toxin 'Nabota' continued its upward sales trend. The company's quarterly revenue exceeded KRW 50 billion for the first time, led by the company’s growth in overseas markets. Nabota’s share of Daewoong's specialty drug sales reached nearly 25 percent, driving the company's performance. According to Daewoon
- Company
- 'High immunity vs. high dose’ flu vaccine for older adults
- by Hwang, Byung-woo Aug 13, 2024 05:47am
- Equipped with their respective flu vaccines specialized for people aged 65 and older, Sanofi and CSL Seqirus are seeking to expand their market share in Korea’s influenza (flu) vaccine market, which is driven by vaccines registered in the National Immunization Program (NIP). CSL Seqirus was the first to enter this market last year, followed
- Company
- Hanmi’s Rolvedon posts sales of KRW 20.6 billion in Q2
- by Son, Hyung-Min Aug 13, 2024 05:47am
- Sales of Rolvedon (Korean brand name: Rolontis), a new anti-cancer drug developed by Hanmi Pharmaceutical, are showing signs of recovery in the U.S. market. Hanmi Pharmaceutical's U.S. partner Assertio plans to increase Rolvedon’s market share through new clinical trials that could ensure the drug’s advantage in convenience of administration.
- Company
- JAK inhibitors market size rose 54%↑over the year
- by Kim, Jin-Gu Aug 12, 2024 05:55am
- The market for Janus Kinase (JAK) inhibitors, oral medicines used to treat autoimmune diseases, is growing rapidly following the approval of major medicines for expanded indications. In the first half of the year, the market for JAK inhibitors reached KRW 27.5 billion in outpatient sales, up 54% year over year (YoY). Abbvie's 'Rinvoq
